(Q36548725)

14 August 2017

1 reference

title

Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel (English)

1 reference

14 August 2017

1 reference

gastroesophageal cancer

1 reference

1

Jaffer A Ajani

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

12

1 reference

14 August 2017

page(s)

1627-1631

1 reference

Epidemiology of upper gastrointestinal malignancies

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1627

Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1627

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1627

Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1627

Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1627

Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1627

Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1627

Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1627

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1627

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1627

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1627

10.1517/14656566.7.12.1627

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference